Phosphodiesterase (PDE)
Phosphodiesterase (PDE) is any enzyme that breaks a phosphodiester bond. Usually, people speaking of phosphodiesterase are referring to cyclic nucleotide phosphodiesterases, which have great clinical significance and are described below. However, there are many other families of phosphodiesterases, including phospholipases C and D, autotaxin, sphingomyelin phosphodiesterase, DNases, RNases, and restriction endonucleases, as well as numerous less-well-characterized small-molecule phosphodiesterases. The cyclic nucleotide phosphodiesterases comprise a group of enzymes that degrade the phosphodiester bond in the second messenger molecules cAMP and cGMP. They regulate the localization, duration, and amplitude of cyclic nucleotide signaling within subcellular domains. PDEs are therefore important regulators ofsignal transduction mediated by these second messenger molecules.
Phosphodiesterase (PDE) Isoform Specific Products
-
Phosphodiesterase (PDE)
(550)
View all products
-
PDE1
(60)
View all products
-
PDE2
(51)
View all products
-
PDE3
(93)
View all products
-
PDE4
(197)
View all products
-
PDE5
(97)
View all products
-
PDE6
(22)
View all products
-
PDE7
(28)
View all products
-
PDE9
(19)
View all products
-
PDE10
(53)
View all products
-
PDE11
(13)
View all products
-
PDE12
(2)
View all products
-
PDE8
(11)
View all products
-
Autotaxin
(36)
View all products
All Product Categories
-
Phosphodiesterase (PDE) Inhibitors
(911)
View all products
-
Phosphodiesterase (PDE) Agonists
(3)
View all products
-
Phosphodiesterase (PDE) Antagonists
(3)
View all products
-
Phosphodiesterase (PDE) Activators
(7)
View all products
-
Phosphodiesterase (PDE) Modulators
(8)
View all products
-
Phosphodiesterase (PDE) Degraders
(4)
View all products
-
Phosphodiesterase (PDE) Controls
(8)
View all products
-
Phosphodiesterase (PDE) Substrates
(4)
View all products
-
Phosphodiesterase (PDE) Ligand
(1)
View all products
-
Phosphodiesterase (PDE) Related Products (1005)
Related Products (1005)
-
Antibodies (4)
-
Phosphodiesterase (PDE) Isoform Comparison
-
Avanafil dibenzenesulfonate
0 ImagesCat. No.: HY-18252ACAS No.: 330784-48-0Synonyms: TA1790 dibenzenesulfonateAvanafil (TA-1790) dibenzenesulfonate is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil dibenzenesulfonate activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil dibenzenesulfonate inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil dibenzenesulfonate can be used for the research of erectile dysfunction and osteoporosis.
-
NPD-1335
0 ImagesNPD1335 is a Trypanosoma brucei phosphodiesterase B1 (TbrPDEB1) inhibitor with submicromolar activities against T. brucei parasites. NPD1335 displays a greatly improved cytotoxicity profile. NPD1335 increases intracellular cAMP levels and results in the distortion of the cell cycle and cell death. NPD-1335 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
-
TPN729MA
0 ImagesSynonyms: TPN729 maleateTPN729MA (TPN729 maleate) is a selective phosphodiesterase type 5 (PDE5) inhibitor with an IC50 value of 2.28 nM. TPN729MA affects erectile function and it can be used for the research of erectile dysfunction.
-
Pentoxifylline-d6
0 ImagesSynonyms: BL-191-d6; Oxpentifylline-d6Pentoxifylline-d6 is the deuterium labeled Pentoxifylline. Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation.
-
TPN729
0 ImagesCat. No.: HY-116808CAS No.: 936951-20-1TPN729 is a selective phosphodiesterase type 5 (PDE5) inhibitor with an IC50 value of 2.28 nM. TPN729 affects erectile function and it can be used for the research of erectile dysfunction.
-
Autotaxin-IN-4
0 ImagesCat. No.: HY-135088CAS No.: 2156655-86-4Autotaxin-IN-4 (compound 51), extracted from patent WO2018212534A1, is an Autotaxin inhibitor. Autotaxin-IN-4 has the potential to treat idiopathic pulmonary fibrosis.
-
PDE5-IN-2
0 ImagesCat. No.: HY-112704CAS No.: 2244517-61-9PDE5-IN-2 is a potent, highly selective, and orally active PDE5 inhibitor, with an IC50 of 0.31 nM, less potently inhibits PDE2A, PDE10A, PDE4D2, and PDE6C, with IC50s of 106, 46, 43, 1.2 nM, respectively. Anti-pulmonary arterial hypertension activity.
-
VP3.15
0 ImagesCat. No.: HY-128879CAS No.: 1281681-54-6VP3.15 is a potent, orally bioavailable and CNS-penetrant dual phosphodiesterase (PDE)7- glycogen synthase kinase (GSK)3 inhibitor, with IC50s of 1.59 μM and 0.88 μM for PDE7 and GSK-3, respectively. VP3.15 has neuroprotective and neuroreparative activities, thus as potential combined anti-inflammatory and pro-remyelinating therapies for multiple sclerosis (MS).
-
Andolast
0 ImagesCat. No.: HY-106358ACAS No.: 143330-46-5Synonyms: CR 2039; DizolastAndolast (CR 2039) is an anti-allergic agent. Andolast can inhibit cAMP-phosphodiesterase with an IC50 value of 50 μM. Andolast can be used for the research of asthma.
-
Indimilast
0 ImagesCat. No.: HY-16744CAS No.: 1038825-85-2Indimilast is a PDE4 inhibitor. Indimilast is used for research on dyslipidemia and related diseases.
-
PDE1-IN-3
0 ImagesCat. No.: HY-130262CAS No.: 2370966-46-2PDE1-IN-3, compound 4 (WO2019156861), is a selective human phosphodiesterase 1 (PDE1) inhibitor. PDE1-IN-3 inhibits PDE4D and PDE6AB with IC50 values of 23.99 μM and 10 μM, respectively.
-
MT-3014
0 ImagesCat. No.: HY-128349CAS No.: 1332727-40-8MT-3014 is a potent, highly selective and brain-penetrated phosphodiesterase 10A (PDE 10A) inhibitor, with IC50s of 0.062 nM and 0.09 nM for human PDE 10A and bovine PDE 10A, respectively.
-
PDE5-IN-16
0 ImagesCat. No.: HY-114797CAS No.: 261769-44-2PDE5-IN-16 is a selective phosphodiesterase type 5 (PDE5) inhibitor with an IC50 of 0.8 nM. PDE5-IN-16 enhances the relaxation of corpus cavernosum tissue strips. PDE5-IN-16 is applicable for the research of erectile dysfunction.
-
Cilostazol-d11
0 ImagesCat. No.: HY-17464SCAS No.: 1073608-02-2Cilostazol-d11 is the deuterium labeled Cilostazol. Cilostazol (OPC 13013) is a potent and selective inhibitor of phosphodiesterase (PDE) 3A, the isoform of PDE 3 in the cardiovascular system, with an IC50 of 0.2 μM.
-
Nor-Acetildenafil-d8
0 ImagesCat. No.: HY-131101SCAS No.: 1185117-07-0Nor-Acetildenafil-d8 is the deuterium labeled Nor-Acetildenafil. Nor-Acetildenafil is an Acetildenafil derivative. Acetildenafil is a synthetic agent which acts as a phosphodiesterase inhibitor.
-
Sildenafil-d8
0 ImagesCat. No.: HY-15025S1CAS No.: 951385-68-5Synonyms: UK-92480-d8Sildenafil-d8 is the deuterium labeled Sildenafil. Sildenafil (UK-92480) is a potent phosphodiesterase type 5 (PDE5) inhibitor with an IC50 of 5.22 nM.
-
Udenafil-d7
0 ImagesCat. No.: HY-18253SCAS No.: 1175992-76-3Udenafil-d7 is the deuterium labeled Udenafil. Udenafil (DA8159) is a potent, selective and orally active phosphodiesterase type 5 (PDE5) inhibitor. Udenafil also inhibits cGMP hydrolysis and can be used for erectile dysfunction research.
-
PDE4-IN-28
0 ImagesCat. No.: HY-176234PDE4-IN-28 (Compound G1) is a PDE4D inhibitor (IC50: 29 nM). PDE4-IN-28 inhibits the production of TNF-α and NO (IC50: 13.32 and 2.32 μM, respectively). PDE4-IN-28 exhibits anti-inflammatory, antibacterial and analgesic effects in a rat pressure ulcer (PU) model and promotes HUVEC cell migration, thereby accelerating wound healing.
-
Autotaxin-IN-8
0 ImagesCat. No.: HY-181931CAS No.: 3058084-21-9Autotaxin-IN-8 (Compound 14E) is an orally active Autotaxin inhibitor with an IC50 of 14.2 nM against hAutotaxin. Autotaxin-IN-8 inhibits Autotaxin activity, MAPK activation, LPAR1 and p-ERK1/2. Autotaxin-IN-8 reduces the phosphorylation levels of JNK and p38. Autotaxin-IN-8 decreases collagen deposition in a mouse model of pulmonary fibrosis. Autotaxin-IN-8 can be used in research related to pulmonary fibrosis.
